Iovance Biotherapeutics : 2022 Annual Report

ANNUAL REPORT


2 0 2 2





D E A R S H A R E H O L D E R S :


2022 was a pivotal year for...

Related Keywords

United States ,Delaware ,Washington ,California ,San Carlos ,American ,America ,Iovance Biotherapeutics ,Frederickg Vogt ,Exchange Commission ,Iovance Cell Therapy Center ,Society For Immunotherapy Of Cancer ,Iovance Biotherapeutics Inc ,Securities Exchange ,Nasdaq Stock Market ,Incorporated By Reference ,Incorporation Or Organization ,National Cancer Institute ,Drug Administration ,Annual Meeting ,Non Small Cell Lung ,Cervical Cancers ,African American ,General Counsel ,Mark One ,Exact Name ,Its Charter ,Principal Executive Offices ,Zip Code ,Telephone Number ,Including Area Code ,Each Class ,Securities Exchange Act ,Interactive Data File ,Regulations T ,Sarbanes Oxley Act ,Exchange Act ,Annual Report ,Proxy Statement ,Common Equity ,Related Stockholder Matters ,Issuer Purchases ,Equity Securities ,Financial Condition ,Qualitative Disclosures About Market Risk ,Supplementary Data ,Financial Disclosure ,Executive Officers ,Corporate Governance ,Certain Beneficial Owners ,Related Transactions ,Director Independence ,Accounting Fees ,Financial Statements Schedules ,Looking Statements ,Market Data ,Biologics License Application ,